Search

Your search keyword '"Gartner, Silvia"' showing total 256 results

Search Constraints

Start Over You searched for: Author "Gartner, Silvia" Remove constraint Author: "Gartner, Silvia"
256 results on '"Gartner, Silvia"'

Search Results

1. Impact of COVID-19 infection on lung function and nutritional status amongst individuals with cystic fibrosis: A global cohort study

2. Standards for the care of people with cystic fibrosis (CF); Planning for a longer life

3. Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues

4. Standards for the care of people with cystic fibrosis; establishing and maintaining health

6. Standards for the care of people with cystic fibrosis (CF): A timely and accurate diagnosis

8. Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis

9. The effect of inhaled hypertonic saline on lung structure in children aged 3–6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial

10. Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study

11. Geographic distribution and phenotype of European people with cystic fibrosis carrying A1006E mutation

12. Incidence and Prevalence of Children's Diffuse Lung Disease in Spain

13. Updated guidance on the management of children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID)

14. Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study

15. Implementation of a gene panel for genetic diagnosis of primary ciliary dyskinesia

16. Implementación de un panel de genes para el diagnóstico genético de la discinesia ciliar primaria

17. Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: Incidence and results of the national CF-COVID19-Spain survey

18. Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis

20. Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues

21. ALPINE2:Efficacy and safety of 14-day vs 28-day inhaled aztreonam for Pa eradication in children with cystic fibrosis

22. Standards for the care of people with cystic fibrosis; establishing and maintaining health

26. Standards for the care of people with cystic fibrosis; establishing and maintaining health

30. Cystic Fibrosis Cases Missed by Newborn Bloodspot Screening—Towards a Consistent Definition and Data Acquisition

33. Elevated Prostaglandin E 2 Synthesis Is Associated with Clinical and Radiological Disease Severity in Cystic Fibrosis.

34. SARS‐CoV‐2 infection in children with cystic fibrosis: A cross‐sectional multicenter study in Spain. New waves, new knowledge

35. ALPINE2: Efficacy and safety of 14-day vs 28-day inhaled aztreonam for Pa eradication in children with cystic fibrosis

39. Incidence and Prevalence of Children's Diffuse Lung Disease in Spain

40. European survey of newborn bloodspot screening for CF: opportunity to address challenges and improve performance

41. Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis

42. European survey of newborn bloodspot screening for CF: opportunity to address challenges and improve performance

43. SARS-CoV-2 infection in children with Cystic Fibrosis: A Cross-sectional Multicenter Study in Spain. New waves, new knowledge.

44. Spanish Consensus on the Prevention and Treatment of Pseudomonas aeruginosa Bronchial Infections in Cystic Fibrosis Patients

45. Consenso español para la prevención y el tratamiento de la infección bronquial por Pseudomonas aeruginosa en el paciente con fibrosis quística

48. Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study

49. Follow-up protocol of patients with cystic fibrosis diagnosed by newborn screening

Catalog

Books, media, physical & digital resources